• If you are wondering whether Kenvue's current share price lines up with its underlying worth, this article walks through what the numbers are actually saying about value.
• Kenvue shares last closed at US$17.54, with returns of 1.4% over 7 days, 0.1% over 30 days, 1.3% year to date and a 21.8% decline over the past year.
• Recent coverage has focused on Kenvue's position as a standalone consumer health company following its separation from Johnson & Johnson and how investors are assessing the stock as a pure play on household and personal products. Headlines have also highlighted ongoing interest in the company's brand portfolio, which shapes how the market thinks about both risk and long term prospects.
• On Simply Wall St's valuation checks, Kenvue scores a 2 out of 6. The next sections will compare different valuation methods, then close with a broader way to think about what that score really means.

Kenvue scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Kenvue Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company could be worth by projecting its future cash flows and discounting them back to today, so you can compare that value to the current share price.

For Kenvue, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $1.74b. Analysts provide explicit estimates for the next few years, and Simply Wall St then extrapolates those out further. Under this framework, projected free cash flow for 2030 is $2.74b, with interim yearly figures between 2026 and 2035 discounted back to today.

Adding up these discounted cash flows gives an estimated intrinsic value of US$28.36 per share. Compared with the recent share price of US$17.54, the model implies a 38.2% discount, which points to Kenvue trading below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Kenvue is undervalued by 38.2%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Kenvue Price vs Earnings

For a profitable company like Kenvue, the P/E ratio is a straightforward way to gauge how much you are paying for each dollar of earnings, which is why it is the preferred multiple here. Higher growth expectations and lower perceived risk usually support a higher "normal" P/E, while slower growth or higher risk tend to justify a lower one.

Kenvue currently trades on a P/E of 22.9x. That sits above the Personal Products industry average of about 20.0x and above the peer group average of 17.9x, so on simple comparisons the shares look more expensive than many competitors.

Simply Wall St's Fair Ratio for Kenvue is 20.0x. This is a proprietary estimate of what Kenvue's P/E might be given factors such as its earnings profile, industry, profit margins, market cap and risk characteristics. Because it blends these company specific inputs, the Fair Ratio can be more tailored than using broad industry or peer averages alone.

Comparing the Fair Ratio of 20.0x with the current P/E of 22.9x suggests Kenvue is trading above this tailored estimate. This indicates that the shares appear overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Kenvue Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Think of a Narrative as your own clear story about Kenvue that links what you believe about its brands, risks and opportunities to a set of numbers for future revenue, earnings and margins. This then rolls into a Fair Value that you can easily compare with today’s share price on Simply Wall St’s Community page, where Narratives are updated as news or earnings arrive and can differ quite a bit. For example, one Kenvue Narrative currently points to a Fair Value of about US$25.09, while another sits closer to US$19.58. This reflects how two investors can look at the same company and reach different but structured conclusions about whether the current price looks high, low or about right.

Do you think there's more to the story for Kenvue? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.